High-Cost Drug Evaluation: Dutch Institute Redu...

By HEOR Staff Writer

May 4, 2026

In High-Cost Drug Evaluation, the Dutch Healthcare Institute Zorginstituut Nederland, announced that the aver...
NICE Endorses Rozanolixizumab for Myasthenia Gravis Treatment
Dementia Pharmacotherapy Guidelines: Emphasizing Non-Pharmacological Approach...
Merck Q1 2026 Performance: Growth and Innovations in Oncology and Cardiometab...
Advancing High-Risk Oncology Interventions: Promising Developments from ASCO ...
Enhancing Breakthrough Medical Device Access: EMA’s New Pilot Program f...
Regulatory Divergence in PSMA Targeted Therapy: Implications for European Mar...
PIONEER TEENS Trial Reveals Oral Semaglutide Diabetes Breakthrough for Pediat...
Terminal Complement Inhibition: Promising Results in IgAN from the I CAN Trial
Advancements in Rare Disease Therapies: CHMP’s April 2026 Insights and ...
Advancements in HIV Two-Drug Regimen: FDA Approves IDVYNSO for Virologically ...
Progress and Challenges in the FDA Accelerated Approval Pathway: A Policy Roa...
Conditional Reimbursement in Chronic Pain Rehabilitation: Navigating Evidence...